Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

51.05
+0.36000.71%
Post-market: 51.250.2000+0.39%16:20 EDT
Volume:339.47K
Turnover:17.26M
Market Cap:3.16B
PE:59.19
High:51.38
Open:50.20
Low:49.91
Close:50.69
Loading ...

Protagonist Therapeutics Shares up 3.9% Premarket After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M

MT Newswires Live
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Inc: Qtrly License and Collaboration Revenue $ 170.6 Mln

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Basic EPS USD 2.11

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Net Income USD 131.674 Million VS. Ibes Estimate USD 22.5 Million

THOMSON REUTERS
·
21 Feb

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire
·
21 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Feb

Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals?

Simply Wall St.
·
14 Feb

Protagonist Therapeutics participates in a conference call with Truist

TIPRANKS
·
08 Feb

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial

TIPRANKS
·
07 Feb

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
07 Feb

Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics

TIPRANKS
·
07 Feb

Positive Outlook on Protagonist Therapeutics: Potential of Rusfertide in Addressing Polycythemia Vera Needs

TIPRANKS
·
07 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
07 Feb

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Feb

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

ACCESS Newswire
·
30 Jan

Protagonist Therapeutics Reports Granting of Inducement Awards

ACCESSWIRE
·
07 Jan